1. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Issue 1 (April 2018) Authors: White, Jay; Shenoy, B.; Tutrone, Ronald; Karsh, Lawrence; Saltzstein, Daniel; Harmon, William; Broyles, Dennis; Roddy, Tamra; Lofaro, Lori; Paoli, Carly; Denham, Dwight; Reynolds, Mark Journal: Prostate cancer and prostatic diseases Issue: Volume 21:Issue 1(2018) Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. (January 2019) Authors: Shore, Neal; Tutrone, Ronald; Roehrborn, Claus G. Journal: Therapeutic advances in urology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL. (May 2022) Authors: Crawford, E. David; Smith, Matthew R.; Tombal, Bertrand; Fizazi, Karim; Hussain, Maha; Sternberg, Cora N.; Rezazadeh Kalebasty, Arash; Tutrone, Ronald; Shore, Neal D.; Belkoff, Laurence; Thiele, Silke; Li, Rui; Kuss, Iris; Joensuu, Heikki; Saad, Fred Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e1038 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MP27-15 SABIZABULIN HAS BOTH CYTOTOXIC AND CYTOSTATIC ACTIVITY IN PHASE 1B/2 CLINICAL OF MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PROGRESSED ON ANDROGEN RECEPTOR TARGETING AGENTS. (May 2022) Authors: Markowski, Mark; Eisenberger, Mario; Pieczonka, Christopher; Getzenberg, Robert; Rodriguez, Domingo; Barnette, K. Gary; Steiner, MItchell; Saltzstein, Daniel; Antonarakis, Emmanuel; Tutrone, Ronald Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MP27-16 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: DETAILED SAFETY ANALYSIS FROM THE RANDOMIZED PHASE 3 HERO STUDY. (May 2022) Authors: Mehlhaff, Bryan; Shore, Neal D.; George, Daniel J.; Cookson, Michael S.; Saltzstein, Daniel R.; Tutrone, Ronald; Bailen, James L.; Brown, Bruce; Langenberg, Andria G.M.; Fallick, Mark; Lu, Sophia; Hanson, Sarah; Tombal, Bertrand; Saad, Fred Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. MP27-17 NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY. (May 2022) Authors: Chi, Kim; Fleshner, Neil; Chiuri, Scaranos, Vincenzo Emanuele; Van Bruwaene, Siska; Hafron, Jason; McNeel, Douglas G.; De Porre, Peter; Maul, R. Scott; Daksh, Mahesh; Zhong, Xiaogang; Mason, Gary E.; Tutrone, Ronald Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PD35-08 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: POOLED SAFETY ANALYSES FROM RANDOMIZED CONTROLLED STUDIES. (1st May 2022) Authors: Bailen, James L.; Saad, Fred; George, Daniel J.; Mehlhaff, Bryan; Cookson, Michael S.; Saltzstein, Daniel R.; Tutrone, Ronald; Brown, Bruce; Langenberg, Andria G. M.; Lu, Sophia; Lee, Jina; Hanson, Sarah; Tombal, Bertrand; Shore, Neal D. Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e630 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. (4th November 2015) Authors: Haas, Naomi B; Stein, Mark N; Tutrone, Ronald; Perini, Rodolfo; Denker, Andrew; Mauro, David; Fong, Lawrence Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. Issue 2 (December 2015) Authors: Haas, Naomi; Stein, Mark; Tutrone, Ronald; Perini, Rodolfo; Denker, Andrew; Mauro, David; Fong, Lawrence Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Reply to Letter to the Editor re: 'Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting'. Issue 4 (November 2018) Authors: White, Jay; Tutrone, Ronald Journal: Prostate cancer and prostatic diseases Issue: Volume 21:Issue 4(2018) Page Start: 604 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗